Gsa Capital Partners LLP Infinity Pharmaceuticals, Inc. Transaction History

Gsa Capital Partners LLP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.7 $191,622 - $552,132	324,784 New	324,784 $386,000
Q2 2022 Aug 09, 2022	SELL	$0.49 - $1.2 $137,006 - $335,526	-279,605 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$0.85 - $2.4 $237,664 - $671,052	279,605 New	279,605 $319,000
Q4 2021 Feb 14, 2022	SELL	$1.86 - $3.36 $167,173 - $301,990	-89,878 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$1.52 - $3.82 $194,269 - $488,230	-127,809 Reduced 58.71%	89,878 $307,000
Q2 2021 Aug 05, 2021	BUY	$2.66 - $3.47 $579,047 - $755,373	217,687 New	217,687 $651,000
Q4 2018 Feb 12, 2019	SELL	$1.01 - $2.78 $287,197 - $790,504	-284,354 Closed	0 $0
Q3 2018 Nov 13, 2018	SELL	$1.72 - $2.71 $9,460 - $14,905	-5,500 Reduced 1.9%	284,354 $771,000
Q2 2018 Aug 09, 2018	SELL	$1.72 - $2.26 $21,156 - $27,797	-12,300 Reduced 4.07%	289,854 $554,000
Q1 2018 May 11, 2018	BUY	$1.8 - $2.74 $519,300 - $790,490	288,500 Added 2112.93%	302,154 $635,000
Q4 2017 Feb 14, 2018	BUY	$1.22 - $3.73 $16,657 - $50,929	13,654	13,654 $28,000

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.